| dc.creator |
AKÇAM, Füsun Zeynep; SÜLEYMAN DEMİREL ÜNİVERSİTESİ |
|
| dc.date |
2021-06-05T00:00:00Z |
|
| dc.date.accessioned |
2021-12-03T11:46:51Z |
|
| dc.date.available |
2021-12-03T11:46:51Z |
|
| dc.identifier |
https://dergipark.org.tr/tr/pub/sdutfd/issue/62643/903161 |
|
| dc.identifier |
10.17343/sdutfd.903161 |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/94087 |
|
| dc.description |
COVİD-19 enfeksiyonu seyrinde birlikte görülen bakteriyel enfeksiyonlar klinik durumu ağırlaştırmaktadır. Bakteriyel bir enfeksiyon varlığı tespit edildiğinde uygun antibakteriyel ajanlarla tedavi yoluna gidilmelidir. Bakteriyel enfeksiyon varlığı kanıtlanmaya çalışılmalıdır. Gereksiz antibiyotik kullanımından kaçınılmaya çalışılmalıdır. Aksi takdirde tüm dünya için tehdit oluşturucu bir boyuta ulaşan antimikrobiklere karşı direnç gelişiminin artmasına olumsuz katkı sağlamış oluruz. |
|
| dc.description |
In the course of COVID-19 infection, bacterial infections aggravate the clinical situation. When a bacterial infection is detected, with appropriate antibacterial agents should be treated. It should be tried to be proven that clinic situation's may be bacterial infection origin. Unnecessary use of antibiotics should be avoided. Otherwise, we will make a negative contribution to the increase in resistance development, which has reached a threatening level for the whole world. |
|
| dc.format |
application/pdf |
|
| dc.language |
tr |
|
| dc.publisher |
Süleyman Demirel Üniversitesi |
|
| dc.publisher |
Süleyman Demirel University |
|
| dc.relation |
https://dergipark.org.tr/tr/download/article-file/1661994 |
|
| dc.source |
Volume: COVID-19 Özel Sayı, Issue: 1
47-49 |
en-US |
| dc.source |
1300-7416 |
|
| dc.source |
2602-2109 |
|
| dc.source |
SDÜ Tıp Fakültesi Dergisi |
|
| dc.subject |
COVİD-19,koenfeksiyon,antibakteriyel,antibiyotik |
|
| dc.subject |
COVID-19,coinfection,antibacterial,antibiotic |
|
| dc.title |
COVİD-19 ve Rasyonel Antibiyotik Kullanımı |
tr-TR |
| dc.title |
COVID-19 and Rational Antibiotic Usage |
en-US |
| dc.type |
info:eu-repo/semantics/article |
|
| dc.citation |
1. https://www.cdc.gov/drugresistance/index.html Erişim: 22.03.2021 |
|
| dc.citation |
2. World Health Organization (WHO) Resolution WHA67.25. Antimicrobial resistance. Sixty seventh World Health Assembly 2014. http://apps.who.int/gb/ebwha/pdffiles/WHA67/A67R25en.pdf?ua=1&ua=1 |
|
| dc.citation |
3. Nujić K, Banjanac M, Munić V, Polančec D, Eraković Haber V. Impairment of lysosomal functions by azithromycin and chloroquine contributes to antiinflammatory phenotype. Cell Immunol. 2012; 279(1): 78–86 |
|
| dc.citation |
4. Min JY, Yong JJ. Macrolid therapy in respiratory viral infedtions. Mediators Inflamm 2012; 2012: 649570. doi: 10.1155/2012/649570. Epub 2012 Jun 6 |
|
| dc.citation |
5. Lee N, Wong CK, Chan MCW, Yeung ESL, Tam WWS, Tsang OTY et. al. Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: A randomized controlled trial. Antiviral Res 2017 Aug;144:48-56. doi: 10.1016/j.antiviral.2017.05.008. Epub 2017 May 20 |
|
| dc.citation |
6. Kakeya H, Seki M, Izumikawa K, Kosai K, Morinaga Y, Kurihara S et.al. Efficacy of combination therapy with oseltamivir phosphate and azithromycin for influenza: a multicenter, open-label, randomized study. PLoS One. 2014 Mar 14;9(3):e91293. doi: 10.1371/journal.pone.0091293. eCollection 2014 |
|
| dc.citation |
7. Echeverría-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME, De-Antonio CuscóM, FerrándezO, HorcajadaJP et.al. Azithromycin in the treatment of COVID-19: a review. Expert Rev Anti InfectTher.2021Feb;19(2):147-163. doi: 10.1080/14787210.2020.1813024. Epub 2020 Oct 6 |
|
| dc.citation |
8. Nanshan Chen, Min Zhou, Xuan Dong, Jieming Qu, Fengyun Gong, Yang Han et.al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020 15-21 February; 395(10223): 507–513 |
|
| dc.citation |
9. Klein EY, Monteforte B, Gupta A, Jiang W, May L, Hsieh YH et.al. The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza Other Respir Viruses. 2016 Sep;10(5):394-403. doi: 10.1111/irv.12398 |
|
| dc.citation |
10. Chen XI, Liao B, Cheng L, Peng X, Xu X, Li Y et.al. The microbial coinfection in COVID-19. Applied Microbiology and Biotechnology https://doi.org/10.1007/s00253-020-10814-6 |
|
| dc.citation |
11. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et.al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507–513. https://doi.org/10.1016/s0140-6736(20)30211-7 |
|
| dc.citation |
12. Ardal C, Balasegaram M, Laxminarayan R, McAdams D, Outterson K, Rex JH et.al. Antibiotic development - economic, regulatory and societal challenges. Nat Rev Microbiol 2020; 18(5):267– 274. https://doi.org/10.1038/s41579-019-0293-3 |
|
| dc.citation |
13. Lippi G, Plebani M. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks. Clin Chem Lab Med. 2020 Jun 25;58(7):1063-1069. doi: 10.1515/cclm-2020-0240 |
|
| dc.citation |
14. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et.al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061–9 https://doi.org/10.1001/jama.2020.1585 |
|
| dc.citation |
15. Tsui TL, Huang YT, Kan WC, Huang MS, Lai MY, Chang Ueng K et. al. A novel procalcitonin based score for detecting sepsis among critically ill patients. PLOS ONE 2021; 16(1): e0245748. https://doi.org/10.1371/journal.pone.0245748 |
|
| dc.citation |
16. Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use NICE guideline Published: 18 August 2015 https://www.nice.org.uk/guidance/ng15 |
|